Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer, June 2022

Free Subscription


Abstracts

Retrieve all available abstracts of the following 272 articles:
HTML format


 

Single Articles

  1. OUSATI ASHTIANI Z, Abbasi S, Pourmand G, Ghafouri-Fard S, et al
    Overexpression of long intergenic noncoding RNAs in bladder cancer: A new insight to cancer diagnosis.
    Pathol Res Pract. 2022;235:153961.
    PubMed    
    Abstract available

  2. ABD EL-SALAM MA, Smith CEP, Pan CX
    Insights on recent innovations in bladder cancer immunotherapy.
    Cancer Cytopathol. 2022 Jun 2. doi: 10.1002/cncy.22603.
    PubMed    
    Abstract available

  3. KIM H, Roh Y, Yong Park S, Lee C, et al
    In vitro and in vivo anti-tumor efficacy of krill oil against bladder cancer: Involvement of tumor-associated angiogenic vasculature.
    Food Res Int. 2022;156:111144.
    PubMed    
    Abstract available

  4. HUANG C, Ai X, Hu L, Ren D, et al
    The Role of NMP22 and CSTB Levels in Predicting Postoperative Recurrence of Bladder Cancer.
    J Immunol Res. 2022;2022:6735310.
    PubMed    
    Abstract available

  5. JIANG Y, Zeng Z, Xiong S, Jiang M, et al
    New Prognostic Gene Signature and Immune Escape Mechanisms of Bladder Cancer.
    Front Cell Dev Biol. 2022;10:775417.
    PubMed    
    Abstract available

  6. ZHANG X, Wang Y, Zhang J, Zhang L, et al
    Development of a MRI-Based Radiomics Nomogram for Prediction of Response of Patients With Muscle-Invasive Bladder Cancer to Neoadjuvant Chemotherapy.
    Front Oncol. 2022;12:878499.
    PubMed    
    Abstract available

  7. XIONG Y, Pang M, Du Y, Yu X, et al
    The LINC01929/miR-6875-5p/ADAMTS12 Axis in the ceRNA Network Regulates the Development of Advanced Bladder Cancer.
    Front Oncol. 2022;12:856560.
    PubMed    
    Abstract available

  8. ZHONG X, Lin T, Shen Y, Zhang P, et al
    Non-muscle-invasive bladder cancer with metastasis to cervical lymph nodes without local recurrence or progression: A case report.
    Asian J Surg. 2022 May 26. pii: S1015-9584(22)00622.
    PubMed    


  9. CHENG X, Wang Y, Li Y, Liu W, et al
    Quantification of ferroptosis pattern in bladder carcinoma and its significance on immunotherapy.
    Sci Rep. 2022;12:9066.
    PubMed    
    Abstract available

  10. HWANG TI, Chen PC, Tsai TF, Lin JF, et al
    Correction: Hsa-miR-30a-3p overcomes the acquired protective autophagy of bladder cancer in chemotherapy and suppresses tumor growth and muscle invasion.
    Cell Death Dis. 2022;13:514.
    PubMed    


  11. KOU B, Gao Y, Du C, Shi Q, et al
    Corrigendum to 'miR-145 inhibits invasion of bladder cancer cells by targeting PAK1'.
    Urol Oncol. 2022 May 28. pii: S1078-1439(22)00179.
    PubMed    


  12. SEVERGINA LO, Kislyakov DA, Korovin IA, Sorokin NI, et al
    [Interpretation of biopsy material after transuretral and laser en bloc resection of non-muscle-invasive bladder cancer].
    Arkh Patol. 2022;84:32-39.
    PubMed    
    Abstract available

  13. AHMADINEZHAD M, Arshadi M, Hesari E, Sharafoddin M, et al
    Relationship between metabolic syndrome and its components with bladder cancer: a systematic review and meta-analysis in cohort studies.
    Epidemiol Health. 2022 May 30:e2022050. doi: 10.4178/epih.e2022050.
    PubMed    
    Abstract available

  14. FANG Z, Yang X, Wei X, Yang Y, et al
    EDARADD silencing suppresses the proliferation and migration of bladder cancer cells.
    Urol Oncol. 2022 May 27. pii: S1078-1439(22)00148.
    PubMed    
    Abstract available

  15. VALENZA C, Antonarelli G, Giugliano F, Aurilio G, et al
    Emerging treatment landscape of non-muscle invasive bladder cancer.
    Expert Opin Biol Ther. 2022 May 31:1-18. doi: 10.1080/14712598.2022.2082869.
    PubMed    
    Abstract available

  16. YOUSSIEF AA, Gamal DA, El-Naggar MS, Zarzor MA, et al
    Could Concurrent Capecitabine with Hypofractionated Radiotherapy in Elderly Patients with Muscle-Invasive Bladder Cancer be an Option?
    Asian Pac J Cancer Prev. 2022;23:1733-1740.
    PubMed    
    Abstract available

  17. FARSHID S, Alijanpour A, Barahman M, Dastgheib SA, et al
    Associations of MTHFR rs1801133 (677C>T) and rs180113 (1298A>C) Polymorphisms with Susceptibility to Bladder Cancer: A Systematic Review and Meta-Analysis.
    Asian Pac J Cancer Prev. 2022;23:1465-1482.
    PubMed    
    Abstract available

  18. ARSLAN AI, Karabag S, Akgul M
    Histiocytic Sarcoma with Invasive Urothelial Carcinoma of Urinary Bladder.
    J Coll Physicians Surg Pak. 2022;32:S79-S81.
    PubMed    
    Abstract available

  19. KALKAN G, Ahsen H, Yalcin B
    Cutaneous Metastasis from Transitional Cell Carcinoma of Urinary Bladder.
    J Coll Physicians Surg Pak. 2022;32:S58-S60.
    PubMed    
    Abstract available

  20. STARMANS MPA, Ho LS, Smits F, Beije N, et al
    Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography.
    J Pers Med. 2022;12.
    PubMed    
    Abstract available

  21. ECKE TH, Le Calvez-Kelm F, Otto T
    Molecular Diagnostic and Prognostication Assays for the Subtyping of Urinary Bladder Cancer Are on the Way to Illuminating Our Vision.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  22. GENG R, Harland N, Montes-Mojarro IA, Fend F, et al
    CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro?
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  23. KOTOLLOSHI R, Gajda M, Grimm MO, Steinbach D, et al
    Wnt/beta-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  24. AUDISIO M, Buttigliero C, Turco F, Delcuratolo MD, et al
    Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?
    Cells. 2022;11.
    PubMed    
    Abstract available

  25. KOIMTZIS G, Alexandrou V, Chalklin CG, Carrington-Windo E, et al
    The Role of Adjuvant Single Postoperative Instillation of Gemcitabine for Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Diagnostics (Basel). 2022;12.
    PubMed    
    Abstract available

  26. LEE CU, Song W, Koo MJ, Boo Y, et al
    Utility of Contemporary Health Screening in the Diagnosis of Bladder Cancer.
    Diagnostics (Basel). 2022;12.
    PubMed    
    Abstract available

  27. BARONE B, Calogero A, Scafuri L, Ferro M, et al
    Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  28. STROGGILOS R, Frantzi M, Zoidakis J, Mokou M, et al
    Gene Expression Monotonicity across Bladder Cancer Stages Informs on the Molecular Pathogenesis and Identifies a Prognostic Eight-Gene Signature.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  29. HIRANO S, Matsumoto K, Tanaka K, Amano N, et al
    DJ-1 Expression Might Serve as a Biologic Marker in Patients with Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  30. MADEJ A, Forma E, Golberg M, Kaminski R, et al
    (13)C Natural Isotope Abundance in Urothelium as a New Marker in the Follow-Up of Patients with Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  31. JAGUVA VASUDEVAN AA, Hoffmann MJ, Poschmann G, Petzsch P, et al
    Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression.
    Sci Data. 2022;9:240.
    PubMed    
    Abstract available

  32. BLACK PC, Alimohamed N, Kassouf W, Gore JL, et al
    Building the Canadian Bladder Cancer Research Network (CBCRN): Progress during a pandemic.
    Can Urol Assoc J. 2022;16:E307-E314.
    PubMed    


  33. MOLLICA V, Massari F, Rizzo A, Ferrara R, et al
    Genomics and Immunomics in the Treatment of Urothelial Carcinoma.
    Curr Oncol. 2022;29:3499-3518.
    PubMed    
    Abstract available

  34. AMENYOGBE A, Lemire F, Yachnin D, Carrier M, et al
    A survey of physician perception and practices regarding pharmacological thromboprophylaxis during chemotherapy for bladder cancer.
    Can Urol Assoc J. 2022 May 20. pii: cuaj.7865. doi: 10.5489/cuaj.7865.
    PubMed    
    Abstract available

  35. YOU S, Kim M, Widen S, Yu A, et al
    Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients.
    Urol Oncol. 2022 May 23. pii: S1078-1439(22)00141.
    PubMed    
    Abstract available

  36. SUKEZAKI A, Kato S, Makise N, Watadani T, et al
    Pseudotumoral cystitis mimicking malignancy in a child.
    Pediatr Int. 2022;64:e15160.
    PubMed    


  37. MASUDA H, Kato M, Yoshiuchi H, Yukimatsu N, et al
    [A Case of Metastatic Urothelial Carcinoma with Pseudoprogression of Liver Metastasis during the Treatment with Pembrolizumab].
    Hinyokika Kiyo. 2022;68:117-121.
    PubMed    
    Abstract available

  38. DI SCIASCIO L, Ambrosi F, Franceschini T, Giunchi F, et al
    Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions?
    Pathol Res Pract. 2022;234:153937.
    PubMed    
    Abstract available

  39. HOSKOPPAL D, Ren Q, Huang H, Park K, et al
    Malignant lymphoma of the lower urinary tract: A single institutional experience.
    Pathol Res Pract. 2022;234:153932.
    PubMed    
    Abstract available

  40. SINGH J, Farooq S, Joshi S, Osunkoya AO, et al
    Histopathologic findings in patients who have undergone blue light cystoscopy and bladder biopsy or transurethral resection: A contemporary clinicopathologic analysis of 100 cases.
    Pathol Res Pract. 2022;234:153916.
    PubMed    
    Abstract available

  41. MANTIA CM, Sonpavde G
    Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Expert Rev Anticancer Ther. 2022;22:449-455.
    PubMed    
    Abstract available

  42. WANG T, Niu X, Zhong B
    Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification.
    Jpn J Clin Oncol. 2022;52:642-649.
    PubMed    
    Abstract available

  43. PARK JH, Park I, Kim IH, Hur JY, et al
    Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure.
    Curr Probl Cancer. 2022;46:100848.
    PubMed    
    Abstract available

  44. CELTIK K, Lim K, Dursun F, Xu J, et al
    Association Between Perioperative Chemotherapy and Survival in Men Undergoing Radical Resection for Primary Urethral Urothelial Carcinoma: An Analysis of the National Cancer Database.
    Clin Genitourin Cancer. 2022;20:244-251.
    PubMed    
    Abstract available

  45. GROSSMANN NC, Pradere B, D'Andrea D, Schuettfort VM, et al
    Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study.
    Clin Genitourin Cancer. 2022;20:227-236.
    PubMed    
    Abstract available

  46. COLOMER GALLARDO A, Candela L, Buisan Rueda O, Freixa Sala R, et al
    The Cancer of the Bladder Risk Assessment (COBRA) score accurately predicts cancer-specific survival after radical cystectomy: external validation and lymphovascular invasion assessment value to improve its performance.
    Clin Genitourin Cancer. 2022;20:199-209.
    PubMed    
    Abstract available

  47. AWADALLA A, Zahran MH, Abol-Enein H, Zekri AN, et al
    Identification of Different miRNAs and Their Relevant miRNA Targeted Genes Involved in Sister Chromatid Cohesion and Segregation (SCCS)/chromatin Remodeling Pathway on T1G3 Urothelial Carcinoma (UC) Response to BCG Immunotherapy.
    Clin Genitourin Cancer. 2022;20:e181-e189.
    PubMed    
    Abstract available

  48. KRAFFT U, Mahmoud O, Hess J, Radtke JP, et al
    Comparative analysis of Bricker versus Wallace ureteroenteric anastomosis and identification of predictors for postoperative ureteroenteric stricture.
    Langenbecks Arch Surg. 2022;407:1233-1240.
    PubMed    
    Abstract available

  49. GETZ K, Mamtani R, Hubbard RA
    Integrating real world data and clinical trial results using survival data reconstruction and marginal moment-balancing weights.
    J Biopharm Stat. 2022;32:191-203.
    PubMed    
    Abstract available

  50. TSUJI S, Reil K, Nelson K, Proclivo VH, et al
    Intravesical VAX014 Synergizes with PD-L1 Blockade to Enhance Local and Systemic Control of Bladder Cancer.
    Cancer Immunol Res. 2022 Jun 9. pii: 704817. doi: 10.1158/2326-6066.CIR-21-0879.
    PubMed    
    Abstract available

  51. FAN B, Teng Q, Sun M, Wang Y, et al
    Assessment of Therapeutic Benefit and Option Strategy on Intravesical Instillation for Preventing Bladder Cancer Recurrence after Radical Nephroureterectomy in Patients with Upper Urinary Tract Urothelial Carcinoma.
    J Oncol. 2022;2022:1755368.
    PubMed    
    Abstract available

  52. WANG Z, Li X, Wang X, Liu J, et al
    Classification of Muscle Invasive Bladder Cancer to Predict Prognosis of Patients Treated with Immunotherapy.
    J Immunol Res. 2022;2022:6737241.
    PubMed    
    Abstract available

  53. WANG Z, He S, Jiang M, Li X, et al
    Mechanism Study on Radiosensitization Effect of Curcumin in Bladder Cancer Cells Regulated by Filamin A.
    Dose Response. 2022;20:15593258221100997.
    PubMed    
    Abstract available

  54. GLOSSER LD, Zakeri BS, Lombardi CV, Ekwenna OO, et al
    Conservative Management of Muscle Invasive Bladder Cancer in Kidney-Pancreas Transplant Patient.
    Case Rep Transplant. 2022;2022:5373414.
    PubMed    
    Abstract available

  55. CHAE HK, Nam W, Kim HG, Lim S, et al
    Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen.
    Front Immunol. 2022;13:903297.
    PubMed    
    Abstract available

  56. LIU Y, Xu X, Wang H, Liu Y, et al
    The Additional Value Evaluation of Tri-parametric MRI in Identifying Muscle-invasive Status in Bladder Cancer.
    Acad Radiol. 2022 Jun 5. pii: S1076-6332(22)00261.
    PubMed    
    Abstract available

  57. FERRO M, Barone B, Crocetto F, Lucarelli G, et al
    Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer.
    Urol Oncol. 2022 Jun 5. pii: S1078-1439(22)00186.
    PubMed    
    Abstract available

  58. CAUSA ANDRIEU PI, Tzeng M
    Inguinal hernia plugs mimicking abdominal wall invasion of bladder cancer - A potential imaging pitfall.
    Radiologia (Engl Ed). 2022;64:274-276.
    PubMed    


  59. KOBAYASHI K, Matsumoto H, Misumi T, Ito H, et al
    The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study.
    Jpn J Clin Oncol. 2022 Jun 9. pii: 6604440. doi: 10.1093.
    PubMed    
    Abstract available

  60. HASAN S, Lazarev S, Garg M, Mehta K, et al
    Racial inequity and other social disparities in the diagnosis and management of bladder cancer.
    Cancer Med. 2022 Jun 8. doi: 10.1002/cam4.4917.
    PubMed    
    Abstract available

  61. SHI R, Wang X, Wu Y, Xu B, et al
    APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases.
    Theranostics. 2022;12:4181-4199.
    PubMed    
    Abstract available

  62. XIONG Y, Song X, Kudusi, Zu X, et al
    Oncogenic GBX2 promotes the malignant behaviors of bladder cancer cells by binding to the ITGA5 promoter and activating its transcription.
    Funct Integr Genomics. 2022 Jun 8. pii: 10.1007/s10142-022-00870.
    PubMed    
    Abstract available



  63. Aktuelle Urol. 2022;53:217-218.
    PubMed    




  64. Aktuelle Urol. 2022;53:217.
    PubMed    


  65. KIM JH, Chang IH
    A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
    Investig Clin Urol. 2022 May 30. pii: 63.e49. doi: 10.4111/icu.20220061.
    PubMed    
    Abstract available

  66. LI H, Chen S, Mi H
    A Multiomics Profiling Based on Online Database Revealed Prognostic Biomarkers of BLCA.
    Biomed Res Int. 2022;2022:2449449.
    PubMed    
    Abstract available

  67. WEI Z, Xu J, Li W, Ou L, et al
    SMARCC1 Enters the Nucleus via KPNA2 and Plays an Oncogenic Role in Bladder Cancer.
    Front Mol Biosci. 2022;9:902220.
    PubMed    
    Abstract available

  68. LOU K, Feng S, Zhang G, Zou J, et al
    Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer.
    Front Oncol. 2022;12:879391.
    PubMed    
    Abstract available

  69. BAEK SW, Mun JY, Jang IH, Yang GE, et al
    YAP1 activation is associated with the progression and response to immunotherapy of non-muscle invasive bladder cancer.
    EBioMedicine. 2022;81:104092.
    PubMed    
    Abstract available

  70. PARK J, Choi YD, Lee K, Seo M, et al
    Quality of life patterns and its association with predictors among non-muscle invasive bladder cancer survivors: A latent profile analysis.
    Asia Pac J Oncol Nurs. 2022;9:100063.
    PubMed    
    Abstract available

  71. XIAO S, Zuo Y, Li Y, Huang Y, et al
    Long Noncoding RNA HAGLROS Promotes the Malignant Progression of Bladder Cancer by Regulating the miR-330-5p/SPRR1B Axis.
    Front Oncol. 2022;12:876090.
    PubMed    
    Abstract available

  72. CONTIERI R, Lughezzani G, Buffi NM, Taverna G, et al
    Could We Safely Avoid a Second Resection in Selected Patients With T1 Non-Muscle-Invasive Bladder Cancer? Preliminary Results of Cost-Effectiveness Study From HUmanitas New Indications for ReTUR (HuNIRe) Multicenter Prospective Trial.
    Front Oncol. 2022;12:879399.
    PubMed    
    Abstract available

  73. ROBELDO T, Ribeiro LS, Manrique L, Kubo AM, et al
    Modified Titanium Dioxide as a Potential Visible-Light-Activated Photosensitizer for Bladder Cancer Treatment.
    ACS Omega. 2022;7:17563-17574.
    PubMed    
    Abstract available

  74. CHI B, Sun Y, Zhao J, Guo Y, et al
    Deoxyschizandrin Inhibits the Proliferation, Migration, and Invasion of Bladder Cancer Cells through ALOX5 Regulating PI3K-AKT Signaling Pathway.
    J Immunol Res. 2022;2022:3079823.
    PubMed    
    Abstract available

  75. YU L, Hu R, Peng G, Ding Q, et al
    Prognostic Significance of Lineage Diversity in Bladder Cancer Revealed by Single-Cell Sequencing.
    Front Genet. 2022;13:862634.
    PubMed    
    Abstract available

  76. PARK C, Choi EO, Hwangbo H, Lee H, et al
    Induction of apoptotic cell death in human bladder cancer cells by ethanol extract of Zanthoxylum schinifolium leaf, through ROS-dependent inactivation of the PI3K/Akt signaling pathway.
    Nutr Res Pract. 2022;16:330-343.
    PubMed    
    Abstract available

  77. HOEH B, Flammia RS, Hohenhorst L, Sorce G, et al
    Outcomes of robotic-assisted versus open radical cystectomy in a large-scale, contemporary cohort of bladder cancer patients.
    J Surg Oncol. 2022 Jun 4. doi: 10.1002/jso.26973.
    PubMed    
    Abstract available

  78. SORIA F, Lucca I, Moschini M, Mathieu R, et al
    Corrigendum to < Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer>, urologic oncology: Seminars and original investigations volume 35, issue 6, June 2017, pages 356-362.
    Urol Oncol. 2022 Jun 1. pii: S1078-1439(22)00176.
    PubMed    


  79. XU N, Yao Z, Shang G, Ye D, et al
    Integrated proteogenomic characterization of urothelial carcinoma of the bladder.
    J Hematol Oncol. 2022;15:76.
    PubMed    
    Abstract available

  80. GOEL A, Ward DG, Noyvert B, Yu M, et al
    Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes.
    Genome Med. 2022;14:59.
    PubMed    
    Abstract available

  81. BESTARI MG, Oktarina A L, Karim MI, Aryanti, et al
    Giant bladder stone resulting in renal failure and concurrent bladder cancer: A case report.
    Int J Surg Case Rep. 2022;94:107170.
    PubMed    
    Abstract available

  82. ZHANG C, Han B, Guo Y, Guan H, et al
    MAP9 Exhibits Protumor Activities and Immune Escape toward Bladder Cancer by Mediating TGF-beta1 Pathway.
    J Oncol. 2022;2022:3778623.
    PubMed    
    Abstract available

  83. HE Y, Wu Y, Liu Z, Li B, et al
    Corrigendum: Identification of Signature Genes Associated With Invasiveness and the Construction of a Prognostic Model That Predicts the Overall Survival of Bladder Cancer.
    Front Genet. 2022;13:880633.
    PubMed    
    Abstract available

  84. WANG H, Shao Z, Xu Z, Ye B, et al
    Antiproliferative and apoptotic activity of gemcitabine-lauric acid conjugate on human bladder cancer cells.
    Iran J Basic Med Sci. 2022;25:536-542.
    PubMed    
    Abstract available

  85. LIU C, Li Z, Ni L
    Analysis of the Significance of miR-141 and CD147 Expression in Bladder Cancer Cells and Its Relationship with Tumor Grade.
    Contrast Media Mol Imaging. 2022;2022:1335441.
    PubMed    
    Abstract available

  86. ZHANG W, Loring M
    Incidental Bladder Cancer at the Time of Routine Cystoscopy following Laparoscopic Hysterectomy.
    JSLS. 2022;26.
    PubMed    
    Abstract available

  87. SYMEONIDIS EN, Lo KL, Chui KL, Vakalopoulos I, et al
    En bloc resection of bladder tumors: challenges and unmet needs in 2022.
    Future Oncol. 2022;18:2545-2558.
    PubMed    
    Abstract available

  88. ELBADAWY M, Fujisaka K, Yamamoto H, Tsunedomi R, et al
    Establishment of an experimental model of normal dog bladder organoid using a three-dimensional culture method.
    Biomed Pharmacother. 2022;151:113105.
    PubMed    
    Abstract available

  89. PANZA E, Bello I, Smimmo M, Brancaleone V, et al
    Endogenous and exogenous hydrogen sulfide modulates urothelial bladder carcinoma development in human cell lines.
    Biomed Pharmacother. 2022;151:113137.
    PubMed    
    Abstract available

  90. SHEN CH, Wu JY, Wang SC, Wang CH, et al
    The suppressive role of phytochemical-induced glutathione S-transferase Mu 2 in human urothelial carcinoma cells.
    Biomed Pharmacother. 2022;151:113102.
    PubMed    
    Abstract available

  91. AHMADI H, Daneshmand S
    Association between use of ERAS protocols and complications after radical cystectomy.
    World J Urol. 2022;40:1311-1316.
    PubMed    
    Abstract available

  92. WANG J, Feng Q, Wu Y, Wang H, et al
    Involvement of blood lncRNA UCA1 in sepsis development and prognosis, and its correlation with multiple inflammatory cytokines.
    J Clin Lab Anal. 2022;36:e24392.
    PubMed    
    Abstract available

  93. DUM D, Menz A, Volkel C, De Wispelaere N, et al
    Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers.
    Exp Mol Pathol. 2022;126:104762.
    PubMed    
    Abstract available

  94. LI H, Huang G, Lai Y, Ni L, et al
    A Panel of Three Serum MicroRNAs as a Potential Diagnostic Biomarker for Urothelial Carcinoma.
    Oncol Res Treat. 2022;45:344-352.
    PubMed    
    Abstract available

  95. SORCE G, Flammia RS, Hoeh B, Chierigo F, et al
    Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients.
    World J Urol. 2022;40:1481-1488.
    PubMed    
    Abstract available

  96. ARAGAKI AK, Jing Y, Hoffman-Censits J, Choi W, et al
    Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature.
    Eur Urol Oncol. 2022;5:338-346.
    PubMed    
    Abstract available

  97. HENSLEY PJ, Bree KK, Brooks N, Matulay J, et al
    Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guerin Therapy Outcomes.
    Eur Urol Oncol. 2022;5:347-356.
    PubMed    
    Abstract available

  98. SORIA F, D'Andrea D, Gontero P, Shariat SF, et al
    Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results fro
    Eur Urol Focus. 2022;8:633-634.
    PubMed    


  99. MONTORSI F, Bandini M, Necchi A
    Re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. Eur Urol Focus 2020;6:1233-9
    Eur Urol Focus. 2022;8:631-632.
    PubMed    


  100. MARCQ G, Foerster B, Abufaraj M, Matin SF, et al
    Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study.
    Eur Urol Focus. 2022;8:491-497.
    PubMed    
    Abstract available

  101. VAN DER KWAST T, Liedberg F, Black PC, Kamat A, et al
    International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma.
    Eur Urol Focus. 2022;8:438-446.
    PubMed    
    Abstract available

  102. JOSHI M, Holder SL, Zhu J, Zheng H, et al
    Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study.
    Eur Urol Focus. 2022;8:483-490.
    PubMed    
    Abstract available

  103. ROSEN G, Anwar T, Syed J, Weinstein D, et al
    Initial Experience with Apixaban for Extended Venous Thromboembolism Prophylaxis After Radical Cystectomy.
    Eur Urol Focus. 2022;8:480-482.
    PubMed    
    Abstract available

  104. COLLA RUVOLO C, Nocera L, Stolzenbach LF, Wenzel M, et al
    Tumor Size Predicts Muscle-invasive and Non-organ-confined Disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy.
    Eur Urol Focus. 2022;8:498-505.
    PubMed    
    Abstract available

  105. MASTROIANNI R, Tuderti G, Anceschi U, Bove AM, et al
    Comparison of Patient-reported Health-related Quality of Life Between Open Radical Cystectomy and Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Interim Analysis of a Randomised Controlled Trial.
    Eur Urol Focus. 2022;8:465-471.
    PubMed    
    Abstract available

  106. TSANG YP, Lau CW
    Outcomes of Partial or Total Cystectomy in Advanced Colon Cancer with Suspected Bladder Invasion-Our 8-Year Experience and Literature Review.
    J Gastrointest Cancer. 2022;53:394-402.
    PubMed    
    Abstract available

  107. MINNELLA EM, Carli F, Kassouf W
    Role of prehabilitation following major uro-oncologic surgery: a narrative review.
    World J Urol. 2022;40:1289-1298.
    PubMed    
    Abstract available

  108. HEINZMANN J, Schneider A, Riener MO
    [Development of a squamous cell carcinoma of the urinary bladder after intravesical condylomas].
    Aktuelle Urol. 2022;53:275-278.
    PubMed    
    Abstract available

  109. WANG SS, Zhai GQ, Chen G, Huang ZG, et al
    Metadherin Promotes the Development of Bladder Cancer by Enhancing Cell Division.
    Cancer Biother Radiopharm. 2022 Jun 14. doi: 10.1089/cbr.2021.0392.
    PubMed    
    Abstract available

  110. MOUSSA M, Chakra MA, Duquesne I
    Intravesical MgSO4 for the treatment of BCG refractory T1 G3 bladder cancer: Preliminary results on efficacy and safety.
    Intractable Rare Dis Res. 2022;11:81-83.
    PubMed    
    Abstract available

  111. SONG P, Lu N, Zhang J, Gao X, et al
    Cause of death of patients with non-muscular invasive, non-metastatic muscular invasive and metastatic bladder cancer after diagnosis.
    Am J Transl Res. 2022;14:3494-3515.
    PubMed    
    Abstract available

  112. TANG H, Li X, Jiang L, Liu Z, et al
    RITA1 drives the growth of bladder cancer cells by recruiting TRIM25 to facilitate the proteasomal degradation of RBPJ.
    Cancer Sci. 2022 Jun 14. doi: 10.1111/cas.15459.
    PubMed    
    Abstract available

  113. CHENG L, Zhang S, Wang M, Lopez-Beltran A, et al
    Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.
    Hum Pathol. 2022 Jun 11. pii: S0046-8177(22)00150.
    PubMed    
    Abstract available

  114. YAO J, Qian K, Chen C, Liu X, et al
    Correction for: ZNF139/circZNF139 promotes cell proliferation, migration and invasion via activation of PI3K/AKT pathway in bladder cancer.
    Aging (Albany NY). 2022;undefined.
    PubMed    


  115. FREUDENBURG E, Bagheri I, Srinivas S, Martinez A, et al
    Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review.
    Cancer Causes Control. 2022 Jun 14. pii: 10.1007/s10552-022-01593.
    PubMed    
    Abstract available

  116. CHEN R, Hu B, Jiang M, Deng W, et al
    Bioinformatic Analysis of the Expression and Clinical Significance of the DNA Replication Regulator MCM Complex in Bladder Cancer.
    Int J Gen Med. 2022;15:5465-5485.
    PubMed    
    Abstract available

  117. LU B, Wei J, Zhou H, Chen J, et al
    Histone H3K36me2 demethylase KDM2A promotes bladder cancer progression through epigenetically silencing RARRES3.
    Cell Death Dis. 2022;13:547.
    PubMed    
    Abstract available

  118. IBRAHIM A, Khalid R, Mohager S, Fadl-Elmula I, et al
    Clinical Characteristics of Urinary Bladder Cancer in the Sudan; Evidence of Pathoetiology Changes.
    Gulf J Oncolog. 2022;1:16-20.
    PubMed    
    Abstract available

  119. DENG L, Jin K, Zhou X, Zhang Z, et al
    Blockade of integrin signaling reduces chemotherapy-induced premature senescence in collagen cultured bladder cancer cells.
    Precis Clin Med. 2022;5:pbac007.
    PubMed    
    Abstract available

  120. TU J, Bao W, Ye X, Wu J, et al
    Laparoscopic radical cystectomy could be used in the clinical surgical treatment of bladder cancer patients.
    Transl Androl Urol. 2022;11:731-732.
    PubMed    


  121. ZHU J, Lu Z, Chen W, Ke M, et al
    Systematic review and meta-analysis on laparoscopic cystectomy in bladder cancer: reply letter.
    Transl Androl Urol. 2022;11:733-734.
    PubMed    


  122. ZHONG W, Qu H, Yao B, Wang D, et al
    Analysis of a Long Non-coding RNA associated Signature to Predict Survival in Patients with Bladder Cancer.
    Cureus. 2022;14:e24818.
    PubMed    
    Abstract available

  123. PARK J, Kamerer RL, Marjanovic M, Sorrells JE, et al
    Label-free optical redox ratio from urinary extracellular vesicles as a screening biomarker for bladder cancer.
    Am J Cancer Res. 2022;12:2068-2083.
    PubMed    
    Abstract available

  124. CHEN MC, Annseles Rajula S, Bharath Kumar V, Hsu CH, et al
    Tannic acid attenuate AKT phosphorylation to inhibit UMUC3 bladder cancer cell proliferation.
    Mol Cell Biochem. 2022 Jun 13. pii: 10.1007/s11010-022-04454.
    PubMed    
    Abstract available

  125. PALMIER M, Monnot A, Teniere T, Cohen Q, et al
    Mycotic arterial aneurysm secondary to BCG intravesical instillation: A review.
    J Med Vasc. 2022;47:94-105.
    PubMed    
    Abstract available

  126. VERGHOTE F, Sargos P, Christodouleas JP, Murthy V, et al
    International Consensus Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy: Update From an IBIS Workgroup.
    Pract Radiat Oncol. 2022 Jun 9. pii: S1879-8500(22)00190.
    PubMed    
    Abstract available

  127. CHIANG Y, Tsai YC, Wang CC, Hsueh FJ, et al
    Tumor-derived C-C motif ligand 2 (CCL2) induces the recruitment and polarization of tumor-associated macrophages and increases the metastatic potential of bladder cancer cells in the postirradiated microenvironment.
    Int J Radiat Oncol Biol Phys. 2022 Jun 9. pii: S0360-3016(22)00598.
    PubMed    
    Abstract available

  128. PRUNTY M, Bukavina L, Mahran A, Mishra K, et al
    Risk factors for postoperative Clostridium difficile infection after radical cystectomy for bladder cancer: a NSQIP database analysis.
    Can J Urol. 2022;29:11170-11174.
    PubMed    
    Abstract available

  129. ZHENG Y, Ye Y, Chen J, Wei Z, et al
    Prevalence and outcomes of transurethral resection versus radical cystectomy for muscle-infiltrating bladder cancer in the United States: A population-based cohort study.
    Int J Surg. 2022;103:106693.
    PubMed    
    Abstract available

  130. ANSARI DJAFARI A, Javanmard B, Razzaghi M, Hojjati SA, et al
    Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial.
    Urol J. 2022 Jun 11. pii: 7194. doi: 10.22037/uj.v19i.7194.
    PubMed    
    Abstract available

  131. ZHAO W, Sun F, Zhang L, Ouyang J, et al
    NEAT1 variant 1 weakens the genome-wide effect of miR-3122 on blocking H3K79me3 in bladder cancer.
    Aging (Albany NY). 2022;14.
    PubMed    
    Abstract available

  132. SENEL C, Asfuroglu A, Aykanat IC, Balci M, et al
    Impact of Urinary pH on the Efficacy of a Postoperative Single Instillation of Mitomycin-C.
    J Coll Physicians Surg Pak. 2022;32:768-772.
    PubMed    
    Abstract available

  133. YANG Y, Yu J, Xiong Y, Xiao J, et al
    Prognostic Analysis of Differentially Expressed DNA Damage Repair Genes in Bladder Cancer.
    Pathol Oncol Res. 2022;28:1610267.
    PubMed    
    Abstract available

  134. ARIAFAR A, Zeighami S, Salehipour M, Ahmed F, et al
    An Investigation of the Pathology Report of Bladder Cancer Patients with Radical Cystectomy in Southern Iran, 2013-2018: A Cross-Sectional Study.
    Med J Islam Repub Iran. 2021;35.
    PubMed    
    Abstract available

  135. WEI Y, Amend B, Todenhofer T, Lipke N, et al
    Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  136. LOKESHWAR SD, Lopez M, Sarcan S, Aguilar K, et al
    Molecular Oncology of Bladder Cancer from Inception to Modern Perspective.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  137. STAKHOVSKYI O, Kobyliak N, Voylenko O, Stakhovskyi E, et al
    Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis.
    Cells. 2022;11.
    PubMed    
    Abstract available

  138. MATSUZAWA N, Nishikawa T, Ohno R, Inoue M, et al
    Paraganglioma of the urinary bladder initially diagnosed as gastrointestinal stromal tumor requiring combined resection of the rectum: a case report.
    World J Surg Oncol. 2022;20:185.
    PubMed    
    Abstract available

  139. ELAWADY T, Khedr A, El-Enany N, Belal F, et al
    Utility of Kolliphor RH 40 in micellar sensitized fluorescence of the novel tyrosine kinase inhibitor "Erdafitinib": Application to human plasma.
    Spectrochim Acta A Mol Biomol Spectrosc. 2022;278:121327.
    PubMed    
    Abstract available

  140. JUN T, Hahn NM, Sonpavde G, Albany C, et al
    Phase II Clinical and Translational Study of Everolimus +/- Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma.
    Oncologist. 2022;27:432-e452.
    PubMed    
    Abstract available

  141. PARK J, Nam A, Lee HB, Jeong SM, et al
    Leiomyosarcoma of urinary bladder in a Shih Tzu dog.
    J Vet Med Sci. 2022;84:799-803.
    PubMed    
    Abstract available

  142. KAJTEZOVIC S, Walker AR, Hjalmarsson B, Bell SG, et al
    Management of secondary Paget's disease of the vulva associated with transitional cell carcinoma.
    J Cancer Res Clin Oncol. 2022;148:1697-1702.
    PubMed    
    Abstract available

  143. SANGUEDOLCE F, Meneghetti I, Bevilacqua G, Montano B, et al
    Intravesical instillation with glycosaminoglycan replacement treatment in patients suffering radiation-induced haemorrhagic cystitis: When and which patients can benefit most from it?
    Urol Oncol. 2022;40:344.
    PubMed    
    Abstract available

  144. WILLIAMS SB, Shan Y, Fero KE, Movva G, et al
    Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma.
    Urol Oncol. 2022;40:345.
    PubMed    
    Abstract available

  145. DAS JP, Woo S, Ghafoor S, Andrieu PIC, et al
    Value of MRI in evaluating urachal carcinoma: A single center retrospective study.
    Urol Oncol. 2022;40:345.
    PubMed    
    Abstract available

  146. UCHIMOTO T, Nakamura K, Komura K, Fukuokaya W, et al
    Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.
    Urol Oncol. 2022;40:344.
    PubMed    
    Abstract available

  147. FUKUOKAYA W, Kimura T, Komura K, Uchimoto T, et al
    Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.
    Urol Oncol. 2022;40:346.
    PubMed    
    Abstract available

  148. WU D, Lee CT, Zynger DL
    Reclassifying pT3 renal pelvic urothelial carcinoma with renal parenchyma invasion to pT2 improves correlation with overall survival.
    Hum Pathol. 2022;125:79-86.
    PubMed    
    Abstract available

  149. SHANMUGAM BK, Rangaraj S, Subramani K, Srinivasan S, et al
    Biomimetic development of chitosan and sodium alginate-based nanocomposites contains zirconia for tissue engineering applications.
    J Biomed Mater Res B Appl Biomater. 2022;110:1942-1955.
    PubMed    
    Abstract available

  150. PATHAK RA, Hemal AK
    Editorial Comment on: "Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair "tetrafecta" Analysis (ROBUUST Collaborative Group)" by Veccia et al.
    J Endourol. 2022;36:760-761.
    PubMed    


  151. MOROZOV A, Babaevskaya D, Taratkin M, Inoyatov J, et al
    Systematic Review: The Learning Curve for Robot-Assisted Radical Cystectomy-What Do We Know?
    J Endourol. 2022;36:770-784.
    PubMed    
    Abstract available

  152. ALBISINNI S, Diamand R, Mjaess G, Aoun F, et al
    Defining the Morbidity of Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Adoption of the Comprehensive Complication Index.
    J Endourol. 2022;36:785-792.
    PubMed    
    Abstract available

  153. DE WIT R, Powles T, Castellano D, Necchi A, et al
    Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
    Br J Clin Pharmacol. 2022;88:3182-3192.
    PubMed    
    Abstract available

  154. VECCIA A, Carbonara U, Djaladat H, Mehazin R, et al
    Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair "tetrafecta" Analysis (ROBUUST Collaborative Group).
    J Endourol. 2022;36:752-759.
    PubMed    
    Abstract available

  155. MUTAGUCHI J, Morooka K, Kobayashi S, Umehara A, et al
    Artificial Intelligence for Segmentation of Bladder Tumor Cystoscopic Images Performed by U-Net with Dilated Convolution.
    J Endourol. 2022;36:827-834.
    PubMed    
    Abstract available

  156. KADONO Y, Kawaguchi S, Nohara T, Shigehara K, et al
    Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST.
    Urol J. 2021;19:202-208.
    PubMed    
    Abstract available

  157. PENG L, Meng C, Li J, You C, et al
    The prognostic significance of controlling nutritional status (CONUT) score for surgically treated renal cell cancer and upper urinary tract urothelial cancer: a systematic review and meta-analysis.
    Eur J Clin Nutr. 2021 Nov 23. pii: 10.1038/s41430-021-01014.
    PubMed    
    Abstract available

  158. ELSHARNOBY O, Fraser N, Williams A, Scriven S, et al
    Bladder urothelial cell carcinoma as a rare cause of haematuria in children: Our experience and review of current literature.
    J Pediatr Surg. 2022;57:1409-1413.
    PubMed    
    Abstract available

  159. WELLIVER C, Feinstein L, Ward JB, Kirkali Z, et al
    Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Prostate Cancer Prostatic Dis. 2022;25:269-273.
    PubMed    
    Abstract available

  160. BAYAT AA, Sadeghi N, Salimi A, Fazli G, et al
    The Association of Cell Surface Fibromodulin Expression and Bladder Carcinoma.
    Urol J. 2021;19:189-195.
    PubMed    
    Abstract available

  161. DA COSTA JB, Gibb EA, Nykopp TK, Mannas M, et al
    Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy.
    Urol Oncol. 2022;40:287-294.
    PubMed    
    Abstract available

  162. HURST CD, Knowles MA
    Mutational landscape of non-muscle-invasive bladder cancer.
    Urol Oncol. 2022;40:295-303.
    PubMed    
    Abstract available

  163. CONDE M, Frew IJ
    Therapeutic significance of ARID1A mutation in bladder cancer.
    Neoplasia. 2022;31:100814.
    PubMed    
    Abstract available

  164. LIU H, Gu J, Huang Z, Han Z, et al
    Fine particulate matter induces METTL3-mediated m(6)A modification of BIRC5 mRNA in bladder cancer.
    J Hazard Mater. 2022;437:129310.
    PubMed    
    Abstract available

  165. JI N, Long M, Garcia-Vilanova A, Ault R, et al
    Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer.
    Cancer Immunol Immunother. 2022 Jun 24. pii: 10.1007/s00262-022-03236.
    PubMed    
    Abstract available

  166. WANG S, Xu D, Gao B, Yan S, et al
    Heterogeneity Analysis of Bladder Cancer Based on DNA Methylation Molecular Profiling.
    Front Oncol. 2022;12:915542.
    PubMed    
    Abstract available

  167. BONDARUK J, Jaksik R, Wang Z, Cogdell D, et al
    The origin of bladder cancer from mucosal field effects.
    iScience. 2022;25:104551.
    PubMed    
    Abstract available

  168. DONG Y, Ding D, Gu J, Chen M, et al
    Alpha-2 Heremans Schmid Glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-beta signalling pathway.
    Bioengineered. 2022;13:14282-14298.
    PubMed    
    Abstract available

  169. TOHI Y, Taoka R, Zhang X, Matsuoka Y, et al
    Antitumor Effects of Orally Administered Rare Sugar D-Allose in Bladder Cancer.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  170. MAESAKA F, Kuwada M, Horii S, Kishi S, et al
    Hypomethylation of CLDN4 Gene Promoter Is Associated with Malignant Phenotype in Urinary Bladder Cancer.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  171. HU S, Gu S, Wang S, Qi C, et al
    Robust Prediction of Prognosis and Immunotherapy Response for Bladder Cancer through Machine Learning Algorithm.
    Genes (Basel). 2022;13.
    PubMed    
    Abstract available

  172. BIERI U, Buser L, Wettstein MS, Eberli D, et al
    Modified Immunoscore Improves Prediction of Survival Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer-A Retrospective Digital Pathology Study.
    Diagnostics (Basel). 2022;12.
    PubMed    
    Abstract available

  173. MORIWAKI M, Le TT, Sung SY, Jotatsu Y, et al
    Relevance of A Disintegrin and Metalloproteinase Domain-Containing (ADAM)9 Protein Expression to Bladder Cancer Malignancy.
    Biomolecules. 2022;12.
    PubMed    
    Abstract available

  174. CHUGHTAI AA, Pannhausen J, Dinger P, Wirtz J, et al
    Effective Radiosensitization of Bladder Cancer Cells by Pharmacological Inhibition of DNA-PK and ATR.
    Biomedicines. 2022;10.
    PubMed    
    Abstract available

  175. NISHIMURA K, Ishihara H, Kondo T, Toguchi M, et al
    Assessment of Feasibility of Robot-assisted Radical Cystectomy in Patients With Advanced Bladder Cancer Treated With Maintenance Hemodialysis Therapy.
    In Vivo. 2022;36:1801-1806.
    PubMed    
    Abstract available

  176. ZHUANG J, Yang X, Zheng Q, Li K, et al
    Metabolic Profiling of Bladder Cancer Patients' Serum Reveals Their Sensitivity to Neoadjuvant Chemotherapy.
    Metabolites. 2022;12.
    PubMed    
    Abstract available

  177. KAMI REDDY KR, Piyarathna DWB, Kamal AHM, Putluri V, et al
    Lipidomic Profiling Identifies a Novel Lipid Signature Associated with Ethnicity-Specific Disparity of Bladder Cancer.
    Metabolites. 2022;12.
    PubMed    
    Abstract available

  178. TOMIYAMA E, Fujita K, Nakano K, Kuwahara K, et al
    Trop-2 in Upper Tract Urothelial Carcinoma.
    Curr Oncol. 2022;29:3911-3921.
    PubMed    
    Abstract available

  179. YAN Y, Li J, Ye M, Li Z, et al
    Tropomyosin Is Potential Markers for the Diagnosis and Prognosis of Bladder Cancer.
    Dis Markers. 2022;2022:6936262.
    PubMed    
    Abstract available

  180. KAVCIC N, Peric I, Zagorac A, Kokalj Vokac N, et al
    Clinical Evaluation of Two Non-Invasive Genetic Tests for Detection and Monitoring of Urothelial Carcinoma: Validation of UroVysion and Xpert Bladder Cancer Detection Test.
    Front Genet. 2022;13:839598.
    PubMed    
    Abstract available


  181. LncRNA RNF144A-AS1 Promotes Bladder Cancer Progression via RNF144A-AS1/miR-455-5p/SOX11 Axis [Retraction].
    Onco Targets Ther. 2022;15:681-682.
    PubMed    
    Abstract available

  182. RIGIROLI F, Zhang D, Molinger J, Wang Y, et al
    Automated versus manual analysis of body composition measures on computed tomography in patients with bladder cancer.
    Eur J Radiol. 2022;154:110413.
    PubMed    
    Abstract available

  183. ALMASSI N, Whiting K, Toubaji A, Lenis AT, et al
    Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.
    JCO Precis Oncol. 2022;6:e2100392.
    PubMed    
    Abstract available

  184. FACHARZTMAGAZINE R

    MMW Fortschr Med. 2022;164:65.
    PubMed    


  185. EBNER B, Eismann L, Volz Y, Bischoff R, et al
    [Surgical and systemic therapy of bladder cancer].
    MMW Fortschr Med. 2022;164:40-42.
    PubMed    


  186. EISMANN L, Ebner B, Volz Y, Bischoff R, et al
    [Initial symptoms and diagnostics of bladder cancer].
    MMW Fortschr Med. 2022;164:36-39.
    PubMed    


  187. STIEF CG

    MMW Fortschr Med. 2022;164:5.
    PubMed    


  188. IYENGAR PV, Marvin DL, Lama D, Tan TZ, et al
    TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling.
    Mol Cancer Res. 2022 Jun 22. pii: 705055. doi: 10.1158/1541-7786.MCR-20-1029.
    PubMed    
    Abstract available

  189. SMITH TAD, Lane B, More E, Valentine H, et al
    Comparison of multiple gene expression platforms for measuring a bladder cancer hypoxia signature.
    Mol Med Rep. 2022;26.
    PubMed    
    Abstract available

  190. HEO J, Lee J, Nam YJ, Kim Y, et al
    The CDK1/TFCP2L1/ID2 cascade offers a novel combination therapy strategy in a preclinical model of bladder cancer.
    Exp Mol Med. 2022 Jun 21. pii: 10.1038/s12276-022-00786.
    PubMed    
    Abstract available

  191. CULPAN M, Kazan O, Acar HC, Iplikci A, et al
    The probability of residual tumor detection in the second transurethral resection of pT1 urothelial bladder cancer according to the risk factors.
    Actas Urol Esp (Engl Ed). 2022 Jun 17. pii: S2173-5786(22)00045.
    PubMed    
    Abstract available

  192. LU D, Wu Y, Liao S, Xie X, et al
    Delayed ileal neobladder fistula caused by bladder stones: a case report.
    BMC Urol. 2022;22:87.
    PubMed    
    Abstract available

  193. ALKANLI N, Ay A, Aydin PK, Cevik G, et al
    Investigation of the relationship between MTRR A66G, MTR A2756G gene variations and cell anomalies in early diagnosis and progression of bladder cancer.
    Mol Biol Rep. 2022 Jun 17. pii: 10.1007/s11033-022-07597.
    PubMed    
    Abstract available

  194. NAKATA M, Shimbo T, Kihara A, Sato C, et al
    Optimisation of Radiation Therapy in Bladder Preservation Therapy for Patients With Clinical Stage T2N0M0 Bladder Cancer.
    Clin Oncol (R Coll Radiol). 2022 Jun 14. pii: S0936-6555(22)00266.
    PubMed    
    Abstract available

  195. AFFERI L, Lonati C, Montorsi F, Briganti A, et al
    Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer.
    Eur Urol Oncol. 2022 Jun 14. pii: S2588-9311(22)00062.
    PubMed    
    Abstract available

  196. HOUEDE N, Flahault C, Gross-Goupil M, Le Clanche S, et al
    [Locally advanced or metastatic bladder cancer: Identification of barriers and levers of patients' pathway in France].
    Bull Cancer. 2022 Jun 17. pii: S0007-4551(22)00187.
    PubMed    
    Abstract available

  197. KIRYAKOZA LC, Diaz JD, Priluck J, Davis J, et al
    A Case of Bilateral Diffuse Uveal Melanocytic Proliferation in the Setting of Urothelial Carcinoma of the Ureter: A Failed Response to Plasmapheresis.
    Ophthalmic Surg Lasers Imaging Retina. 2022;53:350-353.
    PubMed    
    Abstract available

  198. AWIWI MO, Vikram R
    Radiologic Diagnosis and Staging of Bladder Cancer: An Update.
    J Comput Assist Tomogr. 2022 Jun 18. pii: 00004728-990000000-00056.
    PubMed    
    Abstract available

  199. MATSUE T, Gi M, Shiota M, Tachibana H, et al
    The carbonic anhydrase inhibitor acetazolamide inhibits urinary bladder cancers via suppression of beta-catenin signaling.
    Cancer Sci. 2022 Jun 20. doi: 10.1111/cas.15467.
    PubMed    
    Abstract available

  200. NASROLLAHI H, Ahmed F, Eslahi A, Pilehroud MG, et al
    Sarcomatoid variant of urothelial carcinoma in the renal pelvis with brain metastasis: a case report.
    Pan Afr Med J. 2022;41:233.
    PubMed    
    Abstract available

  201. CHABAUD S, Pellerin E, Caneparo C, Ringuette-Goulet C, et al
    Bladder cancer cell lines adapt their aggressiveness profile to oxygen tension.
    Oncol Lett. 2022;24:220.
    PubMed    
    Abstract available

  202. LU Y, Wang S, Wang Y, Li M, et al
    Current Researches on Nanodrug Delivery Systems in Bladder Cancer Intravesical Chemotherapy.
    Front Oncol. 2022;12:879828.
    PubMed    
    Abstract available

  203. QIAN J, Yang L, Hu S, Gu S, et al
    Feasibility Study on Predicting Recurrence Risk of Bladder Cancer Based on Radiomics Features of Multiphase CT Images.
    Front Oncol. 2022;12:899897.
    PubMed    
    Abstract available

  204. DING L, Xia B, Zhang Y, Liu Z, et al
    Web-Based Prediction Models for Overall Survival and Cancer-Specific Survival of Patients With Primary Urachal Carcinoma: A Study Based on SEER Database.
    Front Public Health. 2022;10:870920.
    PubMed    
    Abstract available

  205. SUN X, Xu H, Liu G, Chen J, et al
    A Robust Immuno-Prognostic Model of Non-Muscle-Invasive Bladder Cancer Indicates Dynamic Interaction in Tumor Immune Microenvironment Contributes to Cancer Progression.
    Front Genet. 2022;13:833989.
    PubMed    
    Abstract available

  206. ZHANG Y, Hua S, Jiang Q, Xie Z, et al
    Identification of Feature Genes of a Novel Neural Network Model for Bladder Cancer.
    Front Genet. 2022;13:912171.
    PubMed    
    Abstract available

  207. TAN WS, Steinberg G, Witjes JA, Li R, et al
    Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group.
    Eur Urol Oncol. 2022 Jun 16. pii: S2588-9311(22)00088.
    PubMed    
    Abstract available

  208. TONG S, Hu X, Li Y
    Serum IL-6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non-muscle-invasive bladder cancer.
    Urol Oncol. 2022 Jun 16. pii: S1078-1439(22)00189.
    PubMed    
    Abstract available

  209. ALATI A, Fabiano E, Geiss R, Mareau A, et al
    Bladder preservation in older adults with muscle-invasive bladder cancer: A retrospective study with concurrent chemotherapy and twice-daily hypofractionated radiotherapy schedule.
    J Geriatr Oncol. 2022 Jun 15. pii: S1879-4068(22)00135.
    PubMed    
    Abstract available

  210. NUMAKURA K, Kobayashi M, Ishida T, Okane K, et al
    Effect of Levofloxacin on the Efficacy and Adverse Events in Intravesical Bacillus Calmette-Guerin Treatment for Bladder Cancer: Results of a Randomized, Prospective, Multicenter Study.
    Eur Urol Focus. 2022 Jun 15. pii: S2405-4569(22)00130.
    PubMed    
    Abstract available

  211. TAYLOR AS, Acosta AM, Al-Ahmadie HA, Mehra R, et al
    Precursors of Urinary Bladder Cancer: Molecular Alterations and Biomarkers.
    Hum Pathol. 2022 Jun 15. pii: S0046-8177(22)00151.
    PubMed    
    Abstract available

  212. QIU T, Chen Y, Meng L, Xu T, et al
    Identification of a metabolism-related gene signature predicting overall survival for bladder cancer.
    Genomics. 2022;114:110402.
    PubMed    
    Abstract available

  213. HUO F, Zhang Y, Li Y, Bu H, et al
    Mannose-targeting concanavalin A-epirubicin conjugate for targeted intravesical chemotherapy of bladder cancer.
    Chem Asian J. 2022 Jun 17. doi: 10.1002/asia.202200342.
    PubMed    
    Abstract available

  214. RIETBERGEN DDD, van Gennep EJ, KleinJan GH, Donswijk M, et al
    Evaluation of the Hybrid Tracer Indocyanine Green-99mTc-Nanocolloid for Sentinel Node Biopsy in Bladder Cancer-A Prospective Pilot Study.
    Clin Nucl Med. 2022 Jun 18. pii: 00003072-990000000-00181.
    PubMed    
    Abstract available

  215. CARRASCO R, Ingelmo-Torres M, Gomez A, Roldan FL, et al
    Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer.
    World J Urol. 2022 Jun 17. pii: 10.1007/s00345-022-04061.
    PubMed    
    Abstract available

  216. SILVA DJ, Mesquita A
    Complete and long-lasting response to immunotherapy: A case report of urothelial cancer.
    Medicine (Baltimore). 2022;101:e28940.
    PubMed    
    Abstract available

  217. LIU Z, Xing L, Zhu Y, Shi P, et al
    Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer.
    Heliyon. 2022;8:e09643.
    PubMed    
    Abstract available

  218. XIAYU K, GuoGang C, CanXuan L, WeiBin X, et al
    Comprehensive Characterization of Necroptosis-Related lncRNAs in Bladder Cancer Identifies a Novel Signature for Prognosis Prediction.
    Dis Markers. 2022;2022:2360299.
    PubMed    
    Abstract available

  219. MEHMOOD S, Alothman KI, Al Rumayyan M, Altaweel WM, et al
    Clinical behavior and survival outcome of urothelial bladder cancer in young adults.
    Urol Ann. 2022;14:162-166.
    PubMed    
    Abstract available

  220. STONE L
    Biomarkers for bladder cancer diagnosis, prognosis, monitoring and treatment.
    Nat Rev Urol. 2022 Jun 16. pii: 10.1038/s41585-022-00620.
    PubMed    


  221. VLAAR JM, Borgman A, Kalkhoven E, Westland D, et al
    Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer.
    Sci Rep. 2022;12:10081.
    PubMed    
    Abstract available

  222. XUE MQ, Wang YL, Wang JC, Wang XD, et al
    Comprehensive analysis of the PD-L1 and immune infiltrates of N6-methyladenosine related long non-coding RNAs in bladder cancer.
    Sci Rep. 2022;12:10082.
    PubMed    
    Abstract available

  223. PATHAK A, Kumar M, Singh SK, Singh U, et al
    Bayesian inference: Weibull Poisson model for censored data using the expectation-maximization algorithm and its application to bladder cancer data.
    J Appl Stat. 2020;49:926-948.
    PubMed    
    Abstract available

  224. HAN L, Li P, Fu X, Huang Z, et al
    Aesculetin inhibits proliferation and induces mitochondrial apoptosis in bladder cancer cells by suppressing the MEK/ERK signaling pathway.
    Anticancer Agents Med Chem. 2022 Jun 15. pii: ACAMC-EPUB-124491.
    PubMed    
    Abstract available

  225. LI R, Xia Y, Chen X, Li X, et al
    Identification of a three-miRNA panel in serum for bladder cancer diagnosis by a diagnostic test.
    Transl Cancer Res. 2022;11:1005-1016.
    PubMed    
    Abstract available

  226. ZHENG W, Zhao Y, Wang T, Zhao X, et al
    Identification of hub genes associated with bladder cancer using bioinformatic analyses.
    Transl Cancer Res. 2022;11:1330-1343.
    PubMed    
    Abstract available

  227. SOLEK J, Kalwas M, Sobczak M, Debska-Szmich S, et al
    Urothelial carcinoma of the prostate with raised beta-hCG levels: a case report.
    J Med Case Rep. 2022;16:238.
    PubMed    
    Abstract available

  228. PAL SK, Somford DM, Grivas P, Sridhar SS, et al
    Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.
    Future Oncol. 2022;18:2599-2614.
    PubMed    
    Abstract available

  229. BHANVADIA RR, Lotan Y
    Progress in the development of tissue-based biomarkers for urothelial cancer.
    Expert Rev Anticancer Ther. 2022;22:605-619.
    PubMed    
    Abstract available

  230. LETICA-KRIEGEL AS, Tin AL, Nash GM, Benfante NE, et al
    Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy.
    Eur J Surg Oncol. 2022;48:1427-1432.
    PubMed    
    Abstract available

  231. QI Y, Toyooka T, Horiguchi H, Koda S, et al
    2-mercaptobenzothiazole generates gamma-H2AX via CYP2E1-dependent production of reactive oxygen species in urothelial cells.
    J Biochem Mol Toxicol. 2022;36:e23043.
    PubMed    
    Abstract available

  232. AL QA'QA' S, Tiwari R, van der Kwast T
    Penile extramammary Paget disease associated with urothelial carcinoma in situ: Case report and literature review.
    J Cutan Pathol. 2022;49:663-668.
    PubMed    
    Abstract available

  233. KBIROU A, Hagguir H, Moataz A, Dakir M, et al
    Acute renal failure and bladder tumors, about 106 cases.
    Nephrol Ther. 2022;18:202-206.
    PubMed    
    Abstract available

  234. XUE W, Hu X, Zhang Y
    The Association of Controlling Nutritional Status (CONUT) Score with Survival in Patients with Surgically Treated Renal Cell Carcinoma and Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Nutr Cancer. 2022;74:1907-1916.
    PubMed    
    Abstract available

  235. WANG B, Hu L, Chen Y, Zhu B, et al
    Aspartate transaminase/alanine transaminase (De Ritis ratio) predicts survival in major burn patients.
    Burns. 2022;48:872-879.
    PubMed    
    Abstract available


  236. Advances in the management of prostate and bladder cancer and recurrent urinary tract infections.
    BJU Int. 2022;129:659-660.
    PubMed    


  237. CONROY S, Hubbard R, Noon AP, Hussain SA, et al
    Case of the month from the University of Sheffield, UK: Expediting definitive treatment in patients with invasive bladder cancer: an MRI-guided pathway.
    BJU Int. 2022;129:691-694.
    PubMed    


  238. VEERATTERAPILLAY R, Geraghty R, Pandian R, Roy C, et al
    Ten-year survival outcomes after radical nephroureterectomy with a risk-stratified approach using prior diagnostic ureteroscopy: a single-institution observational retrospective cohort study.
    BJU Int. 2022;129:744-751.
    PubMed    
    Abstract available

  239. NURMINEN P, Ettala O, Uusitalo-Seppala R, Nummi A, et al
    Incidence of and mortality from Bacille Calmette-Guerin (BCG) infections after BCG instillation therapy.
    BJU Int. 2022;129:737-743.
    PubMed    
    Abstract available

  240. JUBBER I, Mitchell S, Hussain S, Tsoi H, et al
    Social deprivation and bladder cancer: cause or affect for disparities in survival for affected women.
    BJU Int. 2022 Jun 20. doi: 10.1111/bju.15832.
    PubMed    


  241. COMPERAT E, Wasinger G, Oszwald A, Pradere B, et al
    Nonmuscle-invasive bladder cancer, old problems, new insights.
    Curr Opin Urol. 2022;32:352-357.
    PubMed    
    Abstract available

  242. VARTOLOMEI MD, Ferro M, Roth B, Teoh JY, et al
    Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update.
    Curr Opin Urol. 2022 Jun 27. pii: 00042307-990000000-00015.
    PubMed    
    Abstract available

  243. LIU Z, Jin K, Zeng H, Shao F, et al
    B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.
    Eur J Cancer. 2022;171:133-142.
    PubMed    
    Abstract available

  244. SOLANKI AA, Kates MR, Tran PT
    Paving the Road to the Future of Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-year Follow-up of BC2001.
    Eur Urol. 2022 May 28. pii: S0302-2838(22)02343.
    PubMed    


  245. HANEY CM, Kriegmair MC, Michel MS, Stolzenburg JU, et al
    New Evidence and Innovative Approaches to Blinding in Robot-assisted Radical Cystectomy.
    Eur Urol. 2022;81:615-617.
    PubMed    


  246. PEEKER R
    Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Eur Urol. 2022;81:619-620.
    PubMed    


  247. ZENNAMI K, Sumitomo M, Hasegawa K, Kozako M, et al
    Risk factors for postoperative ileus after robot-assisted radical cystectomy with intracorporeal urinary diversion.
    Int J Urol. 2022;29:553-558.
    PubMed    
    Abstract available

  248. TAOKA R, Sugimoto M
    Editorial Comment from Dr Taoka and Dr Sugimoto to Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
    Int J Urol. 2022 Jun 11. doi: 10.1111/iju.14954.
    PubMed    


  249. MATSUMOTO K
    Editorial Comment from Dr Matsumoto to Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
    Int J Urol. 2022 Jun 9. doi: 10.1111/iju.14955.
    PubMed    


  250. ARAI T, Sazuka T, Sato H, Imamura Y, et al
    Efficacy of photodynamic diagnosis-assisted transurethral resection of bladder tumor for T1 bladder cancer: Novel second transurethral resection initiatives utilizing photodynamic diagnosis.
    Int J Urol. 2022 Jun 20. doi: 10.1111/iju.14962.
    PubMed    


  251. NOHARA T
    Editorial Comment to Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods.
    Int J Urol. 2022 Jun 19. doi: 10.1111/iju.14967.
    PubMed    


  252. HE W, Yang J, Gao M, Liu H, et al
    Pelvic reconstruction and lateral prostate capsule sparing techniques improve early continence of robot-assisted radical cystectomy with orthotopic ileal neobladder.
    Int Urol Nephrol. 2022;54:1537-1543.
    PubMed    
    Abstract available

  253. BASOURAKOS SP, Al Hussein Al Awamlh B, Borregales LD, Abrahimi P, et al
    A comparative population-based analysis of peritoneal carcinomatosis in patients undergoing robotic-assisted and open radical cystectomy.
    Int Urol Nephrol. 2022;54:1513-1519.
    PubMed    
    Abstract available

  254. ZHU J, Lu Z, Ke M, Cai X, et al
    Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.
    Int Urol Nephrol. 2022;54:1505-1512.
    PubMed    
    Abstract available

  255. ZENG S, Zhang Z, Xu C
    Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial.
    J Clin Oncol. 2022 Jun 15:JCO2200669. doi: 10.1200/JCO.22.00669.
    PubMed    


  256. STOVER AM, Basak R, Mueller D, Lipman R, et al
    Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2022 May 31:101097JU0000000000002747. doi: 10.1097/JU.0000000000002747.
    PubMed    
    Abstract available

  257. SONG Y, Du Y, Qin C, Bai F, et al
    Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. Letter.
    J Urol. 2022;208:222-223.
    PubMed    


  258. GESSNER KH, Siemens DR, Bjurlin MA
    Re: Does Smoking Cessation Reduce Bladder Cancer Recurrence?
    J Urol. 2022 Jun 21:101097JU0000000000002832. doi: 10.1097/JU.0000000000002832.
    PubMed    


  259. ZHENG X, Liu Z, Zhong J, Zhou L, et al
    Downregulation of HINFP induces senescence-associated secretory phenotype to promote metastasis in a non-cell-autonomous manner in bladder cancer.
    Oncogene. 2022 Jun 6. pii: 10.1038/s41388-022-02371.
    PubMed    
    Abstract available

  260. XIAO H, Li H, Yu G, Xiao W, et al
    [Corrigendum] MicroRNA10b promotes migration and invasion through KLF4 and HOXD10 in human bladder cancer.
    Oncol Rep. 2022;48.
    PubMed    
    Abstract available

  261. PAREEK T, Parmar K, Sharma AP, Kumar S, et al
    Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study.
    Urol Int. 2022 Jun 2:1-7. doi: 10.1159/000524098.
    PubMed    
    Abstract available

  262. KNORR JM, Campbell RA, Cockrum J, Dalton JE, et al
    Neighborhood Socioeconomic Disadvantage Associated With Increased 90-Day Mortality Following Radical Cystectomy.
    Urology. 2022;163:177-184.
    PubMed    
    Abstract available

  263. INOUE T, Miyake M, Nishimura N, Onozawa M, et al
    Association of increased age with decreased response to intravesical instillation of Bacille Calmette-Guerin in patients with high-risk non-muscle invasive bladder cancer: Retrospective multi-institute results from the Japanese Urological Oncology Res
    Urology. 2022 Jun 11. pii: S0090-4295(22)00455.
    PubMed    
    Abstract available

  264. LABBATE CV, Kuchta K, Park S, Agarwal PK, et al
    Incidence of Preoperative Antibiotic Use and Its Association with Postoperative Infectious Complications after Radical Cystectomy.
    Urology. 2022;164:169-177.
    PubMed    
    Abstract available

  265. CHEN J, Cai D, Gong K, Zhu S, et al
    Collecting Duct Carcinoma of the Kidney: Analysis of 74 Cases From Multiple Centers.
    Urology. 2022;164:163-168.
    PubMed    
    Abstract available

  266. ANDERSON AL, Tollefson MK, Frank I, Peffley ND, et al
    Intraoperative Ventilatory Pressures During Robotic Assisted vs Open Radical Cystectomy.
    Urology. 2022;164:157-162.
    PubMed    
    Abstract available

  267. NODIT PG, Bienvenu JM
    Rhabdomyosarcoma of the Urinary Bladder Occurring in an Adult.
    Urology. 2022;164:306-307.
    PubMed    


  268. JEONG SH, Han JH, Jeong CW, Kim HH, et al
    Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor.
    BMC Cancer. 2022;22:631.
    PubMed    
    Abstract available

  269. ZHANG Q, Zhang W, Lin T, Lu W, et al
    Mass cytometry reveals immune atlas of urothelial carcinoma.
    BMC Cancer. 2022;22:677.
    PubMed    
    Abstract available

  270. JIANG L, Chen S, Pan Q, Zheng J, et al
    The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients.
    BMC Cancer. 2022;22:676.
    PubMed    
    Abstract available


  271. Retraction: MicroRNA-137 Upregulation Increases Bladder Cancer Cell Proliferation and Invasion by Targeting PAQR3.
    PLoS One. 2022;17:e0269903.
    PubMed    


  272. ABDELGAWAD A, Hashem A, Mosbah A, Eissa LA, et al
    A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer.
    PLoS One. 2022;17:e0266371.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;